EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness of human T-cell leukemia virus type 1 (HTLV-1) antenatal screening for prevention of mother-to-child transmission

Akiko Kowada iD

PLOS Neglected Tropical Diseases · 21.02.2023 · 17 (2) · e0011129

DOI: 10.1371/journal.pntd.0011129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 21.02.2023. Verfasst von Akiko Kowada. Beteiligte Einrichtung: Department of Occupational Health, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan. Hauptthemen laut MEDLINE: Human T-lymphotropic virus 1, Paraparesis, Tropical Spastic, Leukemia-Lymphoma, Adult T-Cell. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia-lymphoma (ATL) and HTLV-1-associated myelopathy-tropical spastic paraparesis (HAM/TSP) with a poor prognosis. This study aimed to evaluate the cost-effectiveness and health impact of HTLV-1 antenatal screening. Methodology/Principal findings A state-transition model was developed for HTLV-1 antenatal screening and no screening over a lifetime horizon from a healthcare payer perspective. A hypothetical cohort of 30-year-old individuals was targeted. The main outcomes were costs, quality-adjusted life-years (QALYs), life expectancy life-years (LYs), incremental cost-effectiveness ratios (ICERs), HTLV-1 carriers, ATL cases, HAM/TSP cases, ATL-associated deaths, and HAM/TSP-associated deaths. The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). Cost-effectiveness was sensitive to the maternal HTLV-1 seropositivity rate, HTLV-1 transmission rate with long-term breastfeeding from HTLV-1 seropositive mothers to children, and the cost of the HTLV-1 antibody test. HTLV-1 antenatal screening was cost-effective when the maternal HTLV-1 seropositivity rate was greater than 0.0022 and the cost of the HTLV-1 antibody test was lower than US$94.8. Probabilistic sensitivity analysis using a second-order Monte-Carlo simulation showed that HTLV-1 antenatal screening was 81.1% cost-effective at a WTP threshold of US$50,000 per QALY gained. For 10,517,942 individuals born between 2011 and 2021, HTLV-1 antenatal screening costs US$785 million, increases19,586 QALYs and 631 LYs, and prevents 125,421 HTLV-1 carriers, 4,405 ATL cases, 3,035 ATL-associated deaths, 67 HAM/TSP cases, and 60 HAM/TSP-associated deaths, compared with no screening over a lifetime. Conclusion/Significance HTLV-1 antenatal screening is cost-effective and has the potential to reduce ATL and HAM/TSP morbidity and mortality in Japan. The findings strongly support the recommendation for HTLV-1 antenatal screening as a national infection control policy in HTLV-1 high-prevalence countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human T-lymphotropic virus 1Paraparesis, Tropical SpasticLeukemia-Lymphoma, Adult T-CellAdultHumansFemalePregnancyCost-Benefit AnalysisInfectious Disease Transmission, VerticalPrenatal Diagnosis

Autor:innen und Institutionen

  • Department of Occupational Health, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan.

ORCID-Profile: Akiko Kowada

Zitieren

APA

Kowada, A. (2023). Cost-effectiveness of human T-cell leukemia virus type 1 (HTLV-1) antenatal screening for prevention of mother-to-child transmission. PLOS Neglected Tropical Diseases, 17(2), e0011129. https://doi.org/10.1371/journal.pntd.0011129

Vancouver

Kowada A. Cost-effectiveness of human T-cell leukemia virus type 1 (HTLV-1) antenatal screening for prevention of mother-to-child transmission. PLOS Neglected Tropical Diseases. 2023;17(2):e0011129. doi:10.1371/journal.pntd.0011129

BibTeX
@article{Kowada2023,
  author = {Kowada, Akiko},
  title = {Cost-effectiveness of human T-cell leukemia virus type 1 (HTLV-1) antenatal screening for prevention of mother-to-child transmission},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  volume = {17},
  number = {2},
  pages = {e0011129},
  doi = {10.1371/journal.pntd.0011129}
}
Kostenlos starten →